Tamer Ibrahim

Guest Assoc. Prof.

University of Freiburg

Germany

Research Interests

Explore related searches

Professors in Germany

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Tamer Ibrahim is a Guest Associate Professor at the University of Freiburg, Germany. His research focuses on structure-based virtual screening and molecular dynamics, particularly in the context of SARS-CoV-2 and drug discovery for various diseases. Recent publications highlight his work on novel compounds targeting antileishmanial, antimalarial, and cancer therapies.

Articles (10)

Year:

2025

Year:

2025

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Collaborators (1)

Frank Boeckler

University Professor (W3) for Medicinal Chemistry / Drug Design

Eberhard Karls Universität Tübingen

GERMANY

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Tamer Ibrahim

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

Benchmarking the Structure-Based Virtual Screening Performance of Wild-Type and Resistant PfDHFR Using Docking and Machine Learning Re-Scoring

Evaluating the structure-based virtual screening performance of SARS-CoV-2 main protease: A benchmarking approach and a multistage screening example against the wild-type and Omicron variants

In Silico Targeting of Fascin Protein for Cancer Therapy: Benchmarking, Virtual Screening and Molecular Dynamics Approaches

In silico screening of SARS-CoV2 helicase using African natural products: Docking and molecular dynamics approaches

Tetrahydrobenzo[h]quinoline derivatives as a novel chemotype for dual antileishmanial-antimalarial activity graced with antitubercular activity: Design, synthesis and biological evaluation

1,5-Diaryl-1,2,4-triazole Ureas as New SLC-0111 Analogues Endowed with Dual Carbonic Anhydrase and VEGFR-2 Inhibitory Activities

New pyrazolylpyrazoline derivatives as dual acting antimalarial-antileishamanial agents: synthesis, biological evaluation and molecular modelling simulations

In-Silico targeting of SARS-CoV-2 NSP6 for drug and natural products repurposing

Facilitating SARS CoV-2 RNA-Dependent RNA polymerase (RdRp) drug discovery by the aid of HCV NS5B palm subdomain binders: In silico approaches and benchmarking

Development of novel benzofuran-based SLC-0111 analogs as selective cancer-associated carbonic anhydrase isoform IX inhibitors

Collaborators (1)

Frank Boeckler

Make your next move.